Cost-effectiveness analysis of 3 months of weekly rifapentine and isoniazid compared to isoniazid monotherapy in a Canadian arctic setting.

ABSTRACT:

Objective

To assess the cost effectiveness of once weekly rifapentine and isoniazid for 12 weeks (3HP) to the current standard care for latent tuberculosis (TB) infection (LTBI) in Iqaluit, Nunavut.

Design

A cost-effectiveness analysis using a Markov model reflecting local practices for LTBI treatment.

Setting

A remote Canadian arctic community with a high incidence of TB.

Participants

Hypothetical patients with LTBI.

Interventions

The cost effectiveness of 3HP was compared with the existing standard of care in the study region which consists of 9 months of twice weekly isoniazid (9H) given by directly observed therapy.

Outcome measures

Effectiveness was measured in quality-adjusted life years (QALYs) with model parameters were derived from histor

SUBMITTER: Pease C 

PROVIDER: S-EPMC8126298 | biostudies-literature | 2021 May

REPOSITORIES: biostudies-literature